Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SKG1120
- Development stage
- Preclinical
- Lead developer
- Tebao Biotech
- Modality
- Gene Therapies
- Administration
- Ophthalmic
01
Overview
SKG1120 is an investigational gene therapy being developed by Xiamen Tebao Biological Engineering (also known as Amoytop Biotech) for the treatment of hereditary retinal dystrophy. Intended as a first-line therapeutic option, SKG1120 is designed to address the underlying genetic causes of retinal degeneration by delivering functional genetic material to the retina. The program is currently in the preclinical stage of development and represents the company's expansion into advanced genetic medicines for ophthalmic conditions. Specific details regarding the viral vector and the target gene have not been publicly disclosed.
Beyond the preview
Go deeper on SKG1120.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SKG1120.